There is no clinical experience with overdose of eladocagene exuparvovec. In case of overdose, the EMA label advises that symptomatic and supportive treatment, as deemed necessary by the treating physician, is provided. Close clinical observation and monitoring of laboratory parameters for systemic immune response are recommended. Accidental exposure to eladocagene exuparvovec, including contact with skin, eyes, and mucous membranes, is to be avoided.L43642
In vivo studies evaluating the carcinogenic or mutagenic effects of eladocagene exuparvovec have not been performed. No toxicological effects in male or female reproductive organs were detected in animal studies. In rats, no evidence of viral shedding outside of the central nervous system was observed, except for cerebrospinal fluid seven days after eladocagene exuparvovec administration.L43642
Eladocagene exuparvovec is a recombinant adeno-associated virus-2 (AAV2)-based gene therapy that expresses human aromatic L-amino acid decarboxylase (AADC), and it is used to treat AADC deficiency, a fatal and rare genetic disorder that causes severe disability in pediatric patients.L43642,L43672 Patients with AADC have mutations in the dopa decarboxylase (DDC) gene that encodes the AADC enzyme. By promoting the expression of AADC, eladocagene exuparvovec leads to the development of motor function in patients with AADC deficiency. Eladocagene exuparvovec is infused directly into the brain (putamen) by bilateral intraputaminal infusion in one surgical session.L43642
Eladocagene exuparvovec received EMA approval in July 2022.A253697,L43672 Before the approval of this gene therapy, the treatment options for patients with AADC deficiency were limited to attempts to increase monoamine neurotransmitter production, decrease neurotransmitter catabolism via monoamine oxidase (MAO) inhibition and address symptoms.A253687 It was subsequently approved by the FDA in November 2024.L51898,L51893
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.